Healthcare Industry News: neurodegenerative
News Release - May 22, 2012
EnVivo Pharmaceuticals Appoints Alfred Sandrock, M.D., Ph.D., to Board of DirectorsWATERTOWN, Mass.--(Healthcare Sales & Marketing Network)--EnVivo Pharmaceuticals, a company dedicated to developing a broad range of novel central nervous system (CNS) therapies, today announced the appointment of Alfred Sandrock, M.D., Ph.D., to the company’s board of directors. Dr. Sandrock is senior vice president, development sciences and chief medical officer at Biogen Idec (NASDAQ:BIIB ).
“It is an honor to welcome Dr. Sandrock to EnVivo’s board of directors and we look forward to working closely with him as we make key advances across our broad CNS pipeline,” said Kees Been, president and chief executive officer of EnVivo Pharmaceuticals. “Dr. Sandrock brings to EnVivo deep expertise and proven success in shaping the clinical development of treatments for neurological diseases. These insights and perspectives will be instrumental as EnVivo prepares for several key milestones for our CNS programs this year, including the upcoming Phase 2b results of our EVP-6124 program in Alzheimer’s disease and initiating our Phase 3 clinical trial for EVP-6124 in schizophrenia later this year.”
A board-certified neurologist, Dr. Sandrock oversees Biogen Idec’s efforts on all clinical development programs, including those focused on neurodegenerative diseases. Dr. Sandrock is also assistant clinical professor of neurology at Harvard Medical School. His contributions to literature include peer-reviewed articles on axonal regeneration, synapse formation, neurophysiology and multiple sclerosis. Dr. Sandrock holds an M.D. from Harvard Medical School and a Ph.D. in neurobiology from Harvard University. He completed an internship in medicine, a residency and chief residency in neurology, and a clinical fellowship in neuromuscular disease and clinical neurophysiology (electromyography) at Massachusetts General Hospital.
“Biogen Idec shares EnVivo’s commitment to innovative science that can improve the lives of people living with neurodegenerative diseases, particularly those in areas of critical unmet medical need such as Alzheimer’s disease,” said Dr. Sandrock. “I look forward to joining the EnVivo board as the company moves closer to its goal of translating promising research and novel compounds into safe and effective CNS therapies.”
About EnVivo Pharmaceuticals
EnVivo Pharmaceuticals, Inc. and its subsidiaries (“EnVivo Pharmaceuticals” or “EnVivo”) are dedicated to discovering and developing small molecule therapeutics for disorders of the central nervous system (CNS). EnVivo Pharmaceuticals, Inc. is a biotech company located in Watertown, Mass. The company’s focus is on building an integrated company and it is working to convert its broad pipeline into a range of CNS therapies that leverage novel mechanisms of action by altering the progression of disease and providing improvement in cognitive and overall function. EnVivo’s lead product is an alpha-7 nicotinic acetylcholine receptor agonist that has successfully completed a Phase 2b clinical trial in schizophrenia and is currently in an ongoing Phase 2b clinical trial for the treatment of cognitive impairment in Alzheimer’s disease. EnVivo’s other clinical programs include an epigenetics program based on Histone Deacetylase inhibition (HDACi), a Gamma Secretase Modulator program and several preclinical programs, including a potent and selective PDE10 inhibitor program. For more information about EnVivo, visit www.envivopharma.com.
Source: EnVivo Pharmaceuticals
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.